Multidisciplinary clinic visits for multiple system atrophy care
Part of Brain & nervous system clinical trials.
This study involves people with possible or probable multiple system atrophy (MSA) joining a specialized clinic team and attending visits every 4 months. It’s meant to improve care planning and support by bringing different specialists together.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must already be a patient at the UT Southwestern MSA clinic
- You need to be able to attend the multidisciplinary clinic every 4 months
- You must be 18 years or older
- Your diagnosis must be possible or probable MSA
- You must be able to give consent (or the study must be able to get your consent)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 3 trial tests a new oral drug (MSA-01) for people with multiple system atrophy. It aims to see if the drug can slow disease progression and improve daily function.
This study uses brain scans and clinical check-ins to better diagnose and predict how Parkinson-related conditions may progress over time. It may help researchers find markers that explain why symptoms change, and could improve future care.
This study looks at how medical decisions are made for people with multiple system atrophy (MSA). It includes both people with MSA and their unpaid caregivers who live in Austria and speak German. Participants and caregivers will share their experiences through online interviews to help improve future care.
This study is testing whether a single appointment with a team of specialists can improve care for people with atypical Parkinsonian disorders like MSA, PSP, or CBS. You would come to the clinic once for a comprehensive visit, and researchers will see if this helps you and your care partner.
This trial tests a new drug called TEV-56286 for people with Multiple System Atrophy (MSA), a rare brain disorder. It aims to see if the drug can help control symptoms and slow the disease.
This early-phase trial tests a new drug called ALT001 for people with multiple system atrophy (MSA). It aims to see if the drug is safe and may help slow the disease.
Hear when a new Multiple System Atrophy (MSA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.